S&P: Schering-Plough unchanged

Standard & Poor's said that Schering-Plough Corp.'s (A-/stable/A-2) announcement that it will pay $435 million to settle a criminal investigation into its sales, marketing and clinical trial practices does not have an impact on the ratings or outlook on the drug maker.

As part of the settlement, the agency said that Schering-Plough will pay a $180 million fine to the U.S. Attorney's Office for the District of Massachusetts and the U.S. Department of Justice.

Schering-Plough will also pay $255 million to resolve civil suits relating to the investigation, the agency said, noting that the settlement, which is still subject to court approval, removes an uncertainty and puts an end to an investigation that began before new management took over the company in 2003.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.